Immunocore Holdings plc (NASDAQ:IMCR) Sees Significant Growth in Short Interest

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 7,340,000 shares, an increase of 9.4% from the January 15th total of 6,710,000 shares. Approximately 15.1% of the company's stock are sold short. Based on an average trading volume of 264,000 shares, the days-to-cover ratio is presently 27.8 days.

Analysts Set New Price Targets

A number of analysts recently weighed in on IMCR shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research note on Friday, January 10th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 price objective (down from $74.00) on shares of Immunocore in a research note on Friday, December 13th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research note on Monday, January 27th. UBS Group started coverage on shares of Immunocore in a research note on Thursday, October 24th. They issued a "sell" rating and a $24.00 price objective for the company. Finally, Mizuho lowered shares of Immunocore from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $65.64.

Immunocore Stock Performance

IMCR stock traded up $0.10 during trading on Thursday, reaching $29.87. The company had a trading volume of 176,578 shares, compared to its average volume of 213,263. The firm has a 50-day simple moving average of $29.96 and a 200-day simple moving average of $32.23. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -31.44 and a beta of 0.77. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore has a twelve month low of $27.69 and a twelve month high of $72.56.

Institutional Trading of Immunocore

A number of institutional investors have recently bought and sold shares of IMCR. GF Fund Management CO. LTD. acquired a new stake in Immunocore in the 4th quarter worth approximately $25,000. Exchange Traded Concepts LLC boosted its stake in Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after purchasing an additional 1,461 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after purchasing an additional 3,053 shares during the period. NEOS Investment Management LLC boosted its position in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after buying an additional 1,102 shares during the last quarter. Finally, Tema Etfs LLC acquired a new position in Immunocore in the 4th quarter worth approximately $330,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.